Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs SoFi Technologies Inc (SOFI) Price & Performance

Cassava Sciences IncTrade
SoFi Technologies IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs SoFi Technologies Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while SoFi Technologies Inc trades at $18 (market cap $23.40B). The key difference: SoFi Technologies Inc is far larger — about 490.1× Cassava Sciences Inc's market cap, and SoFi Technologies Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNASOFI
Market Cap
$47.75M$23.40B
Sector
HealthFinancials
52-Week High
$4.64$32.21
52-Week Low
$0.87$15.15
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

SoFi Technologies Inc

SoFi Technologies (SOFI) trades at $18.38, up 1.55% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75–$4.85 billion, though EBITDA and earnings outlooks were maintained. The stock's valuation shows a P/E of 37.51 and P/S of 5.73, reflecting growth expectations amid profitability improvements.

The outlook for SOFI is cautiously optimistic, driven by robust member growth, cross-selling success, and a diversified revenue stream. Key opportunities include continued execution on the 'everything app' strategy and potential upside to the $19.50 consensus price target. Risks involve reliance on lending growth, pressure on Technology Platform margins, and sensitivity to Federal Reserve rate decisions. Investors should weigh strong fundamentals against high valuation multiples and competitive fintech pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About SoFi Technologies Inc

SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.

Read more on SOFI